b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31358733</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>27</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>07</Month>\n            <Day>28</Day>\n        </DateRevised>\n        <Article PubModel="Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">2044-5385</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>9</Volume>\n                    <Issue>8</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>07</Month>\n                        <Day>29</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Blood cancer journal</Title>\n                <ISOAbbreviation>Blood Cancer J</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>56</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41408-019-0219-3</ELocationID>\n            <Abstract>\n                <AbstractText>In this phase I/II trial, BID, bendamustine (70, 80, or 90\xe2\x80\x89mg/m<sup>2</sup>), ixazomib (4\xe2\x80\x89mg), and dexamethasone (40\xe2\x80\x89mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one. A 3\xe2\x80\x89+\xe2\x80\x893 dose escalation based on dose-limiting toxicities (DLTs) was employed in phase I (total 15); 2/6 patients developed DLTs (neutropenia and thrombocytopenia) at dose level 3 establishing the recommended phase II dose as bendamustine 80\xe2\x80\x89mg/m<sup>2</sup>, ixazomib 4\xe2\x80\x89mg, and dexamethasone 40\xe2\x80\x89mg. The median age was 67 years (range, 42-72), and 43% were females. Patients received a median of 4 (range, 4-9) prior lines of therapy, of which ~50% were double refractory. In phase II, total 19 patients were treated. With a median follow-up of 17 months, 11% achieved very good partial response, 50% achieved partial response, and 27% achieved stable disease. Median progression free (PFS) and overall (OS) survival were 5.2 months (95% CI, 1.96-8.3) and 23.2 months (95% CI 16.3-30.07). The most frequent adverse events were anemia, thrombocytopenia, leukopenia, nausea, diarrhea, and infections. Peripheral neuropathy was infrequent. BID is a well-tolerated and effective combination therapy for patients with RRMM.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Dhakal</LastName>\n                    <ForeName>Binod</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. bdhakal@mcw.edu.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>D\'Souza</LastName>\n                    <ForeName>Anita</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hamadani</LastName>\n                    <ForeName>Mehdi</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Arce-Lara</LastName>\n                    <ForeName>Carlos</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Schroeder</LastName>\n                    <ForeName>Katrina</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chhabra</LastName>\n                    <ForeName>Saurabh</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shah</LastName>\n                    <ForeName>Nirav N</ForeName>\n                    <Initials>NN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gauger</LastName>\n                    <ForeName>Katelyn</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Keaton</LastName>\n                    <ForeName>Taylor</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pasquini</LastName>\n                    <ForeName>Marcelo</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hari</LastName>\n                    <ForeName>Parameswaran</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>\n                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>29</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Blood Cancer J</MedlineTA>\n            <NlmUniqueID>101568469</NlmUniqueID>\n            <ISSNLinking>2044-5385</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D001896">Boron Compounds</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>71050168A2</RegistryNumber>\n                <NameOfSubstance UI="C548400">ixazomib</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>7S5I7G3JQL</RegistryNumber>\n                <NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>981Y8SX18M</RegistryNumber>\n                <NameOfSubstance UI="D000069461">Bendamustine Hydrochloride</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>TE7660XO1C</RegistryNumber>\n                <NameOfSubstance UI="D005998">Glycine</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000069461" MajorTopicYN="N">Bendamustine Hydrochloride</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001896" MajorTopicYN="N">Boron Compounds</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005998" MajorTopicYN="N">Glycine</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D061214" MajorTopicYN="N">Patient Safety</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>25</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>05</Month>\n                <Day>22</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>28</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31358733</ArticleId>\n            <ArticleId IdType="doi">10.1038/s41408-019-0219-3</ArticleId>\n            <ArticleId IdType="pii">10.1038/s41408-019-0219-3</ArticleId>\n            <ArticleId IdType="pmc">PMC6663939</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'